ETCapital
Venture capitalCambridge · Pre-Seed–Series A · 3 people tracked
Investment thesis
ET Capital invests in high-growth companies applying technology innovation, concentrating on science-based businesses in the Cambridge, Oxford and London cluster. The firm raises and manages a series of funds, having backed ambitious entrepreneurs building outstanding businesses, three of which went public and eight of which achieved profitable exits. Through vehicles such as Cambridge Research & Innovation, UK China Enterprise (targeting science-based businesses able to scale in China), Carbon Order (direct-air carbon capture), and the Carbon13 SEIS funds (climate-focused venture builder businesses), it supports early-stage technology and climate ventures. Its early funds were backed by HSBC and the European Investment Fund.
Source: firm website, verified Aug 3, 2026.
Team · 3 people
from the firm's website & public directories
What they invest in
from 5 of 17 portfolio companiesDeep Tech ×3Biotech ×2Cleantech ×2Healthtech ×2AI & Machine Learning ×1Climate Tech ×1Digital Health ×1Energy ×1
HQs:Canada×1
Investments · 17 tracked
founders shown can be your intro pathADC Therapeutics is a biopharmaceutical company that develops antibody drug conjugates and other therapies focused on hematology and oncology.
BiotechHealthtechMedical Devices
Ameet Mallik(Chief Executive Officer)Jose Carmona(Chief Financial Officer)Mohamed Zaki(Chief Medical Officer)Kristen Harrington-Smith(Chief Commercial Officer)David Ege(Chief Technical Officer)Peter Graham(Chief Legal Officer)
Carbon Engineering is a Direct Air Capture (DAC) technology company, founded in 2009, that develops systems to capture large volumes of CO2 directly from the atmosphere.
CleantechClimate TechDeep TechSquamish, CA
Cellestial Health is a preclinical-stage biotech developing therapies for Parkinson's disease, with a lead candidate rooted in astrocytic network biology.
BiotechDeep TechDigital HealthHealthtech
Dr Nat Hastings(Chief Executive Officer)Dr Shawn Manning(Finance & Operations)Dr Lewis Pennicott(Medicinal Chemistry)
MatNex (Materials Nexus) is a materials design company that uses first-principles computation, machine learning, and materials engineering to design new materials to customer-defined performance and cost specifications, then owns and licenses the resulting material IP.
AI & Machine LearningDeep TechNew Materials
Uses advanced technology to address a disease with significant unmet medical need.
Exits · 1
IPOs and acquisitions across the tracked portfolioADC Therapeutics SANYSE: ADCT
Frequently asked questions
- What stage does ETCapital invest at?
- ETCapital invests at the Pre-Seed, Seed, Series A stages.
- What is ETCapital's typical check size?
- ETCapital typically writes checks of $100K – $952.5K.
- What sectors does ETCapital focus on?
- ETCapital focuses on Biotech, Cleantech, Climate Tech, Consumer, Data & Infrastructure, Deep Tech, Enterprise Software, Hardware, Medical Devices, New Materials, SaaS.
- Where is ETCapital located?
- ETCapital is headquartered in Cambridge, GB.
- Does ETCapital lead rounds?
- ETCapital typically participates in rounds rather than leading them.
Images
Similar investors
Innovobot is an investment and innovation platform focused on deep tech, combining a venture fund (IRV), an innovation studio (Innovobot Labs), and engineering services to foster technologies that address social, industrial and environmental challenges.
Everywhere Ventures is an early-stage venture firm that backs founders globally, supported by a community of founders and operators as LPs.
VenturEast is one of India's longest-standing venture capital fund managers, investing since 1997 and managing over $325 million across more than 100 investments in technology, healthcare, and clean environment.
VantagePoint Capital Partners is a global venture investor backing companies from startup through scale-up, with a particular focus on energy innovation and efficiency.
Hercules Capital is a business development company specializing in venture lending, providing flexible debt and equity capital to venture-backed companies in the life sciences and technology sectors.